• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TRASTUZUMAB DUOCARMAZINE Drug Record

  • Summary
  • Interactions
  • Claims
  • TRASTUZUMAB DUOCARMAZINE chembl:CHEMBL4298178

    Alternate Names:

    TRASTUZUMAB DUOCARMAZINE
    SYD985

    Drug Info:

    (0 More Sources)

    Publications:

    van der Lee et al., 2015, The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers., Mol. Cancer Ther.
    Black et al., 2016, SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression., Mol. Cancer Ther.
  • TRASTUZUMAB DUOCARMAZINE   ERBB2

    Interaction Score: 1.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type uterine corpus serous adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25589493 27256376


    Sources:
    JAX-CKB

  • JAX-CKB: SYD985

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    van der Lee et al., 2015, The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers., Mol. Cancer Ther.
    Black et al., 2016, SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression., Mol. Cancer Ther.

  • ChemblDrugs: chembl:CHEMBL4298178

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21